Fulgent Genetics, Inc.

NasdaqGM:FLGT Stock Report

Market Cap: US$617.1m

Fulgent Genetics Future Growth

Future criteria checks 0/6

Fulgent Genetics is forecast to grow earnings and revenue by 44.3% and 7% per annum respectively. EPS is expected to grow by 47.3% per annum. Return on equity is forecast to be -2.8% in 3 years.

Key information

44.3%

Earnings growth rate

47.3%

EPS growth rate

Healthcare earnings growth16.3%
Revenue growth rate7.0%
Future return on equity-2.8%
Analyst coverage

Low

Last updated06 Mar 2024

Recent future growth updates

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Recent updates

Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Mar 01
Are Investors Undervaluing Fulgent Genetics, Inc. (NASDAQ:FLGT) By 32%?

Fulgent Genetics: Buy Growth Ahead Below Liquidation Value

Feb 21

Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Jan 17
Subdued Growth No Barrier To Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Price

Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Dec 14
Is Fulgent Genetics (NASDAQ:FLGT) Using Debt Sensibly?

Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Aug 09
Fulgent Genetics (NASDAQ:FLGT) Has Debt But No Earnings; Should You Worry?

Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

May 09
Analysts Have Been Trimming Their Fulgent Genetics, Inc. (NASDAQ:FLGT) Price Target After Its Latest Report

Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Apr 19
Fulgent Genetics (NASDAQ:FLGT) Is Looking To Continue Growing Its Returns On Capital

Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Jan 15
Why We Like The Returns At Fulgent Genetics (NASDAQ:FLGT)

Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

Dec 28
Does Fulgent Genetics (NASDAQ:FLGT) Have A Healthy Balance Sheet?

What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Fulgent Genetics, Inc. (NASDAQ:FLGT)? These Analysts Have Been Cutting Their Estimates

Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Oct 27
Why Fulgent Genetics, Inc. (NASDAQ:FLGT) Could Be Worth Watching

Wait For Fulgent Genetics To Grow Up

Oct 13

We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Sep 19
We Like Fulgent Genetics' (NASDAQ:FLGT) Returns And Here's How They're Trending

Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Sep 05
Fulgent Genetics (NASDAQ:FLGT) Seems To Use Debt Rather Sparingly

Fulgent Genetics: Poised To Survive Its Post-Covid Hangover

Jul 26

Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Jul 21
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement

Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Jun 04
Fulgent Genetics (NASDAQ:FLGT) Is Investing Its Capital With Increasing Efficiency

Fulgent Is Putting Its Cash Bonanza To Work

May 15

These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

May 04
These 4 Measures Indicate That Fulgent Genetics (NASDAQ:FLGT) Is Using Debt Safely

Fulgent Genetics: Now The Going Could Get Much Tougher

Apr 10

Fulgent Genetics: COVID Bolstered The Underlying Business

Mar 17

Fulgent Genetics: Somewhat Disappoints With A Marked Slowdown In Its NGS Business

Feb 27

Fulgent Genetics Stock: 35% Off Its Recent Highs - It Is Now A Buy

Feb 09

Fulgent Genetics: Sell Volatility

Jan 26

Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Jan 25
Fulgent Genetics (NASDAQ:FLGT) Has A Rock Solid Balance Sheet

Fulgent Genetics: Improving Outlook, But Shares Aren't Quite A Buy

Jan 09

Fulgent Genetics: Undervalued, High Growth, And A COVID Hedge To Boot

Dec 20

I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Dec 14
I Ran A Stock Scan For Earnings Growth And Fulgent Genetics (NASDAQ:FLGT) Passed With Ease

Fulgent: Now Cheap Enough

Dec 06

Earnings and Revenue Growth Forecasts

NasdaqGM:FLGT - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026351-57N/AN/A2
12/31/2025322-58N/AN/A3
12/31/2024279-69N/AN/A3
12/31/2023289-168527N/A
9/30/2023286-642145N/A
6/30/2023307-493156N/A
3/31/2023365-264257N/A
12/31/2022619143235254N/A
9/30/2022803272277297N/A
6/30/2022925392411429N/A
3/31/2022953461476494N/A
12/31/2021993507515539N/A
9/30/20211,036569554596N/A
6/30/2021910493405453N/A
3/31/2021773417327372N/A
12/31/2020422214105141N/A
9/30/202013548-66N/A
6/30/2020443-11N/A
3/31/202035046N/A
12/31/201933046N/A
9/30/201930-266N/A
6/30/201925-412N/A
3/31/201922-602N/A
12/31/201821-6-4-1N/A
9/30/201820-5-7-3N/A
6/30/201819-6-8-2N/A
3/31/201818-5-8-1N/A
12/31/201719-3-41N/A
9/30/2017200N/A4N/A
6/30/201721-5N/A4N/A
3/31/201720-13N/A5N/A
12/31/201618-14N/A4N/A
9/30/201615-22N/A3N/A
6/30/201613-15N/A2N/A
3/31/201611-6N/A0N/A
12/31/201510-5N/A-1N/A
12/31/20141-1N/A-4N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: FLGT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: FLGT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: FLGT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: FLGT's revenue (7% per year) is forecast to grow slower than the US market (8% per year).

High Growth Revenue: FLGT's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: FLGT is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.